Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).
A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS). Jones, R., Chawla, N., Attia, S., Pollack, S., Cranmer, L. D., Lopez-Pousa, A., Seetharam, M., Burgess, M., Chmielowski, B., Siontis, B. L., Trent, J. C., Wilky, B. A., Bui, N., Chugh, R., Somaiah, N., Van Tine, B., Chawla, S. P. LIPPINCOTT WILLIAMS & WILKINS. 2025View details for DOI 10.1200/JCO.2025.43.16_suppl.11506
View details for Web of Science ID 001690400100010